According to the Market Statsville Group (MSG), the Global Artificial Intelligence in Biotechnology Market size is expected to project a considerable CAGR of 11.5% from 2024 to 2033.
The market for artificial intelligence in biotechnology is projected to gain robust growth because of the increased integration of technology in most biotechnological applications. This has made the process of drug discovery, personalized medicine, genomics, and disease diagnosis more effective and accurate while reducing costs and time. Key players are investing big amounts into research and development in AI to lead the competition, harnessing parts of machine learning, deep learning, and natural language processing in the analysis of complex biological data.
Competition has built partnerships between biotech companies and tech titans to accelerate innovation and broaden the applications of AI. The implementation of regulatory frameworks and huge healthcare demands also support market expansion. Challenges currently lie in data privacy concerns and high costs in implementing AI. Still, on the other hand, the benefits it is seen to have in the biotech processes drive the market momentum. North America currently leads the region, with Europe and Asia-Pacific following, showing regional adoption and technological advancement.
Request Sample Copy of this Report: https://www.marketstatsville.com/request-sample/artificial-intelligence-in-biotechnology-market?utm_source=free&utm_medium=harsh
Definition of the Artificial Intelligence in Biotechnology
AI in the biotechnology market is supported to the extent that AI technologies are being increasingly used to advance and automate biological technology processes. From drug discovery and genomics to personalized medicine and diagnostics, it is enabling and driving efficiency, accuracy, and innovation in machine learning, deep learning, and data analytics in the discovery and development areas of biotech.
Scope of the Global Artificial Intelligence in Biotechnology Market
The study categorizes the Artificial Intelligence in the Biotechnology market based on offering, application, technology, end-users, and usage at the regional and global levels.
By Offering Outlook (Sales, USD Million, 2019-2033)
- Software
- Hardware
- Services
By Applications Outlook (Sales, USD Million, 2019-2033)
- Drug Discovery & Development
- Medical Imaging Analysis
- Genomics & Personalized Medicine
- Others
By Usage Outlook (Sales, USD Million, 2019-2033)
- Medical Biotechnology
- Agriculture Biotechnology
- Animal Biotechnology
- Industrial Biotechnology
By Technology Outlook (Sales, USD Million, 2019-2033)
- Machine Learning (ML)
- Natural Language Processing (NLP)
- Deep Learning
- Computer Vision
By End User Outlook (Sales, USD Million, 2019-2033)
- Pharmaceutical and Biotechnology Companies
- Research and Academic Institutions
- Healthcare Providers
- Contract Research Organizations (CROs)
By Region Outlook (Sales, USD Million, 2019-2033)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- Italy
- France
- UK
- Spain
- Poland
- Russia
- The Netherlands
- Norway
- Czech Republic
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Indonesia
- Malaysia
- Thailand
- Singapore
- Australia & New Zealand
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Colombia
- Rest of South America
- The Middle East & Africa
- Saudi Arabia
- UAE
- South Africa
- Northern Africa
- Rest of MEA
Direct Purchase Report: https://www.marketstatsville.com/buy-now/artificial-intelligence-in-biotechnology-market?opt=3338&utm_source=free&utm_medium=harsh
Genomics & personalized medicine segment accounts for the largest market share by application
Based on the application, the market is divided into drug discovery & development, medical imaging analysis, genomics & personalized medicine, and others. Genomics and personalized medicine are currently ruling the area. This is the area where AI has its maximum leverage in the analysis of huge genomic data in a fast and accurate way so that the treatment plan can be chalked out according to the genotype of the patient. AI has also played a vital part in pushing genomic research forward—by finding genetic markers in diseases and driving activities toward precision medicine.
Integrating AI into personalized medicine not only further advances healthcare outcomes in the prognosis of disease risk but also optimizes treatment responses and acts in the reduction of adverse effects. Furthermore, other continuous general advances occur within the AI algorithms and computational biology frameworks, that extend the abilities and applications within genomics, supporting its overpowering position in the transition of biotechnological practices towards more personalized and effective healthcare solutions.
North America accounted for the largest market share by Region.
Based on the regions, the global market of Artificial Intelligence in Biotechnology has been segmented across North America, Europe, the Middle East & Africa, South America, and Asia-Pacific. North America remains a major market for the penetration of Artificial Intelligence (AI) in biotechnology, considering the following pivotal factors. To be more detailed, the existence of most major biotech companies in this region also holds for large pharmaceutical companies and tech companies at the frontier of AI research. These drive a high investment in research and development on AI through increased machine learning, advanced big data analytics, and assertion gaining for reinforced biotech processes, mostly in the aspects of drug discovery and personalized medicine.
North America provides a facilitative regulatory environment concerning technological improvements, which will ensure faster adoption of AI solutions in healthcare. Besides that, the region will likely gain a lot from its developed healthcare infrastructure and leading academic institutions in developing artificial intelligence talent and fostering collaboration between academia and industry. All these things will place North America at the leading edge of biotechnological innovation through AI, hence propelling the sector into market leadership and further growth.
Competitive Landscape: Global Artificial Intelligence in Biotechnology Market
A very competitive sense at the world market level for artificial intelligence in biotechnology is produced by the confrontation of intense innovation reinforced by strategy in common collaborative partnerships of key players. Top companies are working on proprietary algorithms that will provide advanced AI for drug discovery, genomics, and applications in personalized medicine. The common partnership between biotech firms and technology moguls goes into the very fiber of blend strengths in data analytics and biotechnological competencies for that edge against their rivalries.
Major players in the global Artificial Intelligence in Biotechnology market are:
- Bristol-Myers Squibb
- AstraZeneca
- Sanofi
- Gilead Sciences, Inc.
- Biogen
- Abbott Laboratories
- Novo Nordisk A/S
- Pfizer, Inc.
- Merck KGaA
- Amgen, Inc.
- F. Hoffmann-La Roche Ltd.
- Johnson & Johnson Services, Inc.
- Novartis AG
- Other Major Players
Request For Report TOC: https://www.marketstatsville.com/table-of-content/artificial-intelligence-in-biotechnology-market
Recent Development
- In February 2023, Insilico established the largest AI-powered biotechnology research facility in the region, in Abu Dhabi, to promote the digital transformation of healthcare in the region and enhance the capabilities of its patented Pharma.AI drug discovery platform.
- In January 2023, MeNow, an AI start-up whose mission is centered around understanding candidate molecule dynamics within a computational model of the skin, and Green Mountain Biotech, a raw materials seller developing and supplying state-of-the-art, multifunctional botanical ingredients for skincare, announced great success in the implementation of their bold and creative project for identifying new combinations of plants targeting skin condition.
Comments
Post a Comment